• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Ramius looks to shake up SurModics

Ramius looks to shake up SurModics

November 19, 2010 By MedCity News

MedCity News logo

In the last year alone, SurModics Inc. (NSDQ:SRDX) opened a $41 million pharmaceutical plant, which is bleeding cash, fired its CEO, massively restructured its operations, and is now facing down a potentially nasty proxy fight with an outside investor.

Ramius LLC, the alternative investment arm of Cowen & Co., recently purchased a 12 percent stake in SurModics, making it the largest shareholder, according to documents filed with the Securities & Exchange Commission.

“It appears that both management and the board do not have a strong grasp on the serious business issues facing the company,” Ramius wrote in a letter to the SurModics board.

“Further, we believe the 36.5 percent decline in stock price since reporting fourth quarter results demonstrates that shareholders have become increasingly uncomfortable with the direction of the company.”

The firm said it’s nominating three candidates to SurModics’ board of directors, apparently with the hopes of influencing the selection of the next CEO. The company has been without a permanent top executive since pushing out Bruce Barclay in June.

“Ramius has been very aggressive as SurModics’ stock tanked for the reasons the firm outlined,” said Ernest Andberg, an equity analyst with Feltl & Co., an investment bank in Minneapolis.

For the year, SurModics lost $21.1 million on revenue of $69.9 million compared to a profit of $37.5 million on revenue of $121.5 million the previous 12 months. The company’s big bets on ophthalmology, pharmaceuticals and diagnostics have so far failed to pay off.

“We are disappointed with our fiscal 2010 performance,” interim CEO Phil Ankeny said in a statement. “While the environment remains challenging, and the company continues to navigate through several revenue transitions, we know we are capable of doing better — and we are committed to doing better.”

In October, SurModics laid off 13 percent of its workforce and restructured its operations into three units — medical devices, pharmaceuticals and diagnostics.

Andberg says the company has one good growth business: advanced surface coatings for medical devices like catheters, guide wires, cardiac rhythm leads. The cardiovascular unit squeezed out a 1 percent revenue gain to $40 million, the only business to register a year-over-year sales gain.

But Andberg finds it odd that SurModics would launch a major reorganization effort before hiring a new CEO. Most companies allow their new leaders to develop and lead restructuring efforts.

That could be why Ramius is not currently pushing for a sale or a breakup of the company.

“SurModics is now at a critical juncture,” the company’s letter reads. “Management and the board need assistance in determining the right strategic direction for the company and the right path forward to improve shareholder value. Our nominees have the necessary experience and desire to work constructively with management and the board to address these issues and to assist in identifying and retaining a new chief executive officer to lead the company.”

Andberg says he’s not sure how shareholders will respond to Ramius’ campaign. They may want to give SurModics’ current leadership time to find a new CEO, implement the restructuring plan, and see if the company’s investments in ophthalmology and pharmaceuticals do anything.

Filed Under: Business/Financial News, News Well Tagged With: SurModics Inc.

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy